{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:56:25Z","timestamp":1775742985413,"version":"3.50.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>In England and Wales, replacement of childhood 7-valent pneumococcal conjugate vaccine (PCV7) with a 13-valent vaccine (PCV13) in 2010 was associated with a significant reduction in PCV13-serotype invasive pneumococcal disease (IPD), with a small increase in IPD due to non-vaccine serotypes. Here, we describe the clinical presentation, comorbidity prevalence, serotype distribution and outcomes of childhood IPD during the first 6 years after PCV13 introduction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Public Health England conducts enhanced IPD surveillance in England and Wales, with detailed information requested from general practitioners for all cases in children &lt;5 years of age. Invasive isolates are routinely serotyped at the Public Health England reference laboratory.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>From April 2010 to March 2016, 1280 IPD episodes were confirmed in 1255 children 3\u201359 months of age; 84.3% (1059\/1255) isolates were serotyped. Clinical presentation with meningitis was most prevalent in 3- to 11-month olds (45.8%, 209\/456) and lower respiratory tract infection in 24- to 59-month olds (46.7%, 133\/285). Overall, 259 (20.6%) children had 292 comorbidities, particularly immunosuppression (31.6%, 92\/292). Twenty-one children (1.8%) had recurrent IPD. The case fatality rate was 5.1% (64\/1255; 95% confidence interval [CI]: 3.9%\u20136.5%) and independently associated with meningitis (aOR 3.53; 95% CI: 1.62\u20137.70) and presence of comorbidity (aOR, 2.41; 95% CI: 1.25\u20134.64). In 2015\/2016, PCV13 serotypes were responsible for 10.8% (25\/232) of serotyped cases; the most prevalent non-PCV13 serotypes were 12F (18%), 10A (12%), 23B (10%), 33F (10%), 15B\/C (10%) and 8 (8%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Most childhood IPD cases are now due to non-PCV13 serotypes. A higher proportion of children with IPD have underlying comorbidity, but, reassuringly, the risk of recurrent IPD or death remains low.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001845","type":"journal-article","created":{"date-parts":[[2018,6,10]],"date-time":"2018-06-10T12:59:59Z","timestamp":1528635599000},"page":"697-703","source":"Crossref","is-referenced-by-count":31,"title":["Characteristics of Children With Invasive Pneumococcal Disease After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine in England and Wales, 2010\u20132016"],"prefix":"10.1097","volume":"37","author":[{"given":"Ashley","family":"Makwana","sequence":"first","affiliation":[{"name":"Immunisation Department, Public Health England, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Sheppard","sequence":"additional","affiliation":[{"name":"Respiratory and Vaccine Preventable Bacterial Reference Unit (RVPBRU), Public Health England, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Public Health England, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman","family":"Fry","sequence":"additional","affiliation":[{"name":"Respiratory and Vaccine Preventable Bacterial Reference Unit (RVPBRU), Public Health England, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick J.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Statistics, Modelling and Economics Department, Public Health England, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamez N.","family":"Ladhani","sequence":"additional","affiliation":[{"name":"Immunisation Department, Public Health England, London, United Kingdom"},{"name":"Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St. George\u2019s University of London, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","article-title":"Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.","volume":"11","author":"Miller","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3201\/eid1901.120741","article-title":"Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales.","volume":"19","author":"Ladhani","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2334-10-12","article-title":"Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants.","volume":"10","author":"R\u00fcckinger","year":"2010","journal-title":"BMC Infect Dis"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1183\/09031936.00080814","article-title":"Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types.","volume":"44","author":"Browall","year":"2014","journal-title":"Eur Respir J"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10096-016-2834-2","article-title":"Changes in the pneumococcal disease-related hospitalisations in Spain after the replacement of 7-valent by 13-valent conjugate vaccine.","volume":"36","author":"Georgalis","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1542\/peds.2014-0473","article-title":"Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine.","volume":"134","author":"Iroh Tam","year":"2014","journal-title":"Pediatrics"},{"key":"R9-20230912","article-title":"Changes in the nature and severity of invasive pneumococcal disease in children, before and after the 7-valent and 13-valent pneumococcal conjugate vaccine programs in Calgary, Canada.","author":"Ricketson","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/INF.0000000000000604","article-title":"Differential impact of pneumococcal conjugate vaccines on bacteremic pneumonia versus other invasive pneumococcal disease.","volume":"34","author":"Ben-Shimol","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1016\/j.vaccine.2016.07.038","article-title":"Impact of PCV7\/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: comparison between meningitis and non-meningitis IPD.","volume":"34","author":"Ben-Shimol","year":"2016","journal-title":"Vaccine"},{"key":"R12-20230912","article-title":"Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: insights from Israeli surveillance studies.","author":"Ben-Shimol","year":"2017","journal-title":"Vaccine"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/cid\/civ368","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in US children.","volume":"61","author":"Olarte","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1016\/j.vaccine.2014.03.017","article-title":"Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.","volume":"32","author":"van Hoek","year":"2014","journal-title":"Vaccine"},{"issue":"suppl 1","key":"R15-20230912","first-page":"A4","article-title":"P08 Risk of invasive pneumococcal disease in children with sickle cell disease in England: National observational cohort study, 2010 \u2013 2015.","volume":"102","author":"Oligbu","year":"2017","journal-title":"Arch Dis Childhood"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jinf.2010.04.008","article-title":"The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis.","volume":"61","author":"Jit","year":"2010","journal-title":"J Infect"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201807000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T18:08:53Z","timestamp":1694542133000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201807000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001845","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}